Merck & Co., Inc. (NYSE: MRK) has cleared a critical clinical hurdle for remigromig, the ophthalmology asset acquired through its potentially $3 billion purchase of EyeBio, after both tested doses met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. At 52 weeks, the 0.5-milligram and 0.8-milligram doses were independently non-inferior to 0.5-milligram ranibizumab on mean change from baseline in best-corrected visual acuity, giving Merck & Co. the first late-stage validation of an unusual strategy aimed at repairing the blood-retinal barrier rather than directly blocking VEGF.
The September 24 result is encouraging, but it arrived with a clinically important qualification. Merck & Co. reported higher rates of proliferative diabetic retinopathy, vitreous hemorrhage and treatment discontinuations caused by adverse events in the remigromig arms than among patients receiving ranibizumab. The company has not yet disclosed the actual incidence of those events, the magnitude of visual-acuity gains, confidence intervals or the numerical differences between treatment groups, leaving investors and retinal specialists with a successful headline result but an incomplete understanding of the drug’s risk-benefit profile.
That uncertainty makes the forthcoming full BRUNELLO presentation particularly important. Merck & Co. plans to disclose the one-year results at the American Academy of Ophthalmology Annual Meeting in New Orleans on October 10 and discuss the findings with regulatory authorities. A second pivotal Phase 2b/3 study, BAROLO, is also part of the company’s development program, meaning the commercial future of remigromig will depend on whether efficacy can be reproduced and the emerging ocular safety findings can be sufficiently explained.
Why is remigromig different from existing diabetic macular edema treatments?
Most modern diabetic macular edema therapies revolve around vascular endothelial growth factor, or VEGF, a signaling pathway strongly associated with abnormal vascular leakage in retinal disease. Drugs such as Roche’s Lucentis, Bayer and Regeneron Pharmaceuticals’ Eylea franchise and Roche’s Vabysmo have demonstrated that suppressing vascular signaling can preserve or improve vision, but repeated intravitreal injections remain necessary and a meaningful proportion of patients do not achieve optimal responses.
Remigromig takes a fundamentally different biological approach. The tetravalent, tri-specific antibody is designed to activate the Wingless-related integration site, or Wnt, pathway, which plays a role in repairing and maintaining the inner blood-retinal barrier. Rather than primarily suppressing a leakage-promoting signal, Merck & Co. is attempting to restore a biological system responsible for keeping retinal blood vessels properly sealed.
That distinction explains why the BRUNELLO result has implications beyond a single experimental medicine. Merck & Co. said remigromig represents the first new mechanism in roughly two decades to deliver Phase 3-level results that are non-inferior to anti-VEGF therapy in diabetic macular edema. If later studies confirm a favorable clinical profile, ophthalmologists could eventually gain a therapeutic mechanism that complements rather than simply imitates the VEGF-directed drugs that dominate retinal medicine.
The unmet need remains significant despite the availability of effective anti-VEGF treatments. Merck & Co. estimates that as many as 40% of diabetic macular edema patients do not fully respond to existing therapies and may remain vulnerable to continued vision loss. That creates room for drugs capable of either rescuing inadequate responders or changing the underlying biology of vascular leakage in a different way.
What exactly did the BRUNELLO trial prove, and what remains unknown?
BRUNELLO enrolled 984 adults with diabetic macular edema in a randomized, double-masked study comparing two remigromig dose levels against ranibizumab. During the first year, participants received intravitreal therapy every four weeks, while the second year uses a personalized-treatment-interval algorithm. The pivotal efficacy endpoint evaluates mean change in best-corrected visual acuity from baseline at week 52 using standardized vision testing.
Merck & Co. has confirmed that both remigromig doses satisfied the statistical requirements for non-inferiority to ranibizumab. That means the experimental medicine preserved or improved vision sufficiently closely to the active comparator that the difference remained within the predefined trial margin. Non-inferiority, however, should not be confused with superiority. The announcement does not establish that remigromig produced better vision than ranibizumab.
The missing numerical data will determine how persuasive the efficacy story actually becomes. Investors do not yet know the average number of vision-chart letters gained in each group, the exact treatment differences or whether either remigromig dose showed a numerical advantage. Anatomical measures such as retinal thickness, vascular leakage and fluid resolution will also be closely watched because they may reveal whether activating the Wnt pathway produces biological effects that distinguish remigromig from conventional anti-VEGF therapy.
The safety details could prove even more consequential. Proliferative diabetic retinopathy represents an advanced form of diabetic retinal disease associated with abnormal new blood-vessel formation, while vitreous hemorrhage can impair vision when blood enters the gel filling the eye. Higher event rates in a pivotal study demand careful interpretation, particularly for a treatment intended for chronic use in patients whose vision may otherwise be stabilized using established therapies.
Why does the safety signal matter so much when remigromig met its primary endpoint?
Diabetic macular edema already has several effective approved treatments, so a new medicine faces a different regulatory and commercial threshold from a therapy entering a disease with no alternatives. Merck & Co. does not merely need to show that remigromig works. The company must demonstrate why physicians should use it instead of, or potentially alongside, familiar anti-VEGF drugs with extensive real-world safety experience.
Higher rates of proliferative diabetic retinopathy and vitreous hemorrhage could complicate that argument if the numerical differences prove substantial or appear mechanistically related to Wnt activation. Conversely, the finding could become less concerning if the absolute numbers are small, concentrated among particular high-risk patients or explained by baseline disease characteristics. Merck & Co. said further analyses are underway, making the October presentation a genuine clinical catalyst rather than a ceremonial disclosure of already-known results.
Treatment discontinuations due to adverse events also deserve scrutiny because persistence is commercially important in retinal medicine. A drug capable of maintaining vision but causing more patients to stop treatment may struggle to displace established therapies unless it delivers another meaningful advantage, such as superior retinal drying, improved durability or efficacy in patients who respond poorly to anti-VEGF medicines.
The BRUNELLO topline release did not establish such an advantage. That does not mean remigromig lacks one, only that Merck & Co. has not yet presented enough information to demonstrate it.
Why was Merck & Co. willing to pay up to $3 billion for EyeBio?
Merck & Co. agreed to acquire EyeBio in May 2024 for $1.3 billion upfront and as much as another $1.7 billion in development, regulatory and commercial milestone payments. The deal was completed in July 2024, making EyeBio a wholly owned subsidiary and giving Merck & Co. remigromig, then known as Restoret or EYE103, together with other retinal-development programs.
At the time, remigromig had only early Phase 1/2 evidence from the AMARONE study. Merck & Co. therefore paid a substantial upfront price for a biological hypothesis that had not yet survived a pivotal randomized trial. BRUNELLO materially reduces that development risk by demonstrating that the Wnt agonist can match an established anti-VEGF medicine on the study’s principal visual-acuity endpoint.
The acquisition also represented a diversification move. Merck & Co. remains heavily dependent on Keytruda, whose family generated $8.4 billion in second-quarter 2026 revenue, accounting for roughly half of the company’s $16.6 billion in quarterly sales. The pharmaceutical group has been spending aggressively across cardiovascular disease, immunology, infectious disease and other fields as it tries to build growth engines capable of reducing long-term dependence on its dominant oncology franchise.
Ophthalmology gives Merck & Co. access to another large specialty market where chronic treatment can support substantial recurring revenue. A successful remigromig franchise could also validate EyeBio’s wider scientific platform, potentially making the acquisition strategically more important than the economics of a single diabetic macular edema indication.
How difficult will it be for Merck & Co. to break into the retinal drug market?
The competitive bar is formidable. Anti-VEGF therapy has evolved considerably since monthly ranibizumab established itself as a major retinal treatment. Roche’s Vabysmo and higher-dose Eylea regimens have increasingly emphasized longer treatment intervals, allowing some patients to go months between injections rather than returning every four weeks.
BRUNELLO’s first-year comparison against ranibizumab every four weeks provides a clear efficacy benchmark for regulatory development, but the commercial market in 2026 increasingly revolves around durability. Physicians may ask whether remigromig can eventually reduce injection frequency, rescue suboptimal anti-VEGF responders or produce a complementary biological effect that justifies switching.
The trial design may eventually help answer part of that question. Treatment frequency becomes personalized during the study’s second year, potentially giving Merck & Co. evidence on whether patients can maintain disease control at extended intervals. If remigromig ultimately needs monthly injections indefinitely, non-inferiority to ranibizumab may be insufficient to establish a strong competitive position against newer extended-dosing options.
Merck & Co. is also evaluating the Wnt pathway more broadly across retinal vascular diseases. Its ophthalmology pipeline includes additional remigromig studies and other mechanisms, suggesting the EyeBio acquisition was intended to establish a franchise rather than secure a single asset.
What does the BRUNELLO result mean for Merck & Co. stock sentiment?
Merck & Co. shares closed at $147.98 on September 24, down just 0.07% for the session after trading as high as $151.46. The relatively muted closing reaction suggests investors viewed the positive primary endpoint alongside the unresolved safety findings rather than treating BRUNELLO as an unqualified pipeline win.
That response is understandable given Merck & Co.’s scale. Remigromig remains investigational and has not yet generated revenue, while existing businesses such as Keytruda, Keytruda Qlex and Winrevair already contribute billions of dollars. Winrevair alone generated $588 million in second-quarter sales, up 75%, while Merck & Co. raised its 2026 worldwide sales guidance to between $66.3 billion and $67.3 billion.
The stock-market significance of BRUNELLO therefore lies in pipeline diversification rather than near-term earnings. A successful regulatory path would provide evidence that Merck & Co.’s multibillion-dollar business-development spending is producing viable late-stage assets outside oncology.
What should investors and retina specialists watch next for remigromig?
October 10 is now the critical date. The complete BRUNELLO dataset should reveal the actual vision gains, differences between doses, anatomical retinal outcomes and, most importantly, the incidence and characteristics of proliferative diabetic retinopathy, vitreous hemorrhage and adverse-event-related discontinuations.
Regulatory discussions will follow, but Merck & Co. may need the second pivotal BAROLO study to provide additional confidence around efficacy and safety before the commercial picture becomes clear. BAROLO is expected to provide another late-stage readout in 2027, giving the company a chance to determine whether BRUNELLO’s findings are reproducible across an independent patient population.
For now, Merck & Co. has achieved something scientifically meaningful. A drug based on restoring the Wnt pathway has matched established anti-VEGF therapy on a pivotal visual-acuity endpoint, providing the strongest clinical validation yet for the EyeBio acquisition.
But the story is not simply that Merck & Co.’s $3 billion bet worked. BRUNELLO has simultaneously produced the evidence needed to keep remigromig moving forward and a safety question significant enough that the full dataset could materially change how valuable that success ultimately becomes.
